Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada

International Journal of Drug Policy

Volumn 47, Issue , 2017, Pages 202-208

  Mason, Kate ^a   Dodd, Zoë ^a   Guyton, Mary ^b   Tookey, Paula ^a   Lettner, Bernadette ^a   Matelski, John ^c   Sockalingam, Sanjeev ^c   Altenberg, Jason ^a   Powis, Jeff ^d  

^a South Riverdale Community Health Centre   (Canada)

^b Sherbourne Health Centre   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d TORONTO EAST GENERAL HOSPITAL   (Canada)

Author keywords

Adherence; Community based treatment models; Direct acting antivirals; Hepatitis C; Injection drug use

Indexed keywords

ANTIVIRUS AGENT; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN PLUS SOFOSBUVIR; UNCLASSIFIED DRUG;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANADA; COMMUNITY CARE; CONTROLLED STUDY; CORRELATION ANALYSIS; ETHNICITY; FEMALE; HEALTH PROGRAM; HEALTH STATUS; HEPATITIS C; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL HEALTH; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SOCIAL SUPPORT; SUBSTANCE USE; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; DRUG USE; MIDDLE AGED; PRIMARY HEALTH CARE; PSYCHOLOGY; SUSTAINED VIROLOGIC RESPONSE; VULNERABLE POPULATION;

ANTIVIRAL AGENTS; CANADA; COMMUNITY HEALTH SERVICES; DRUG THERAPY, COMBINATION; DRUG USERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SUSTAINED VIROLOGIC RESPONSE; VULNERABLE POPULATIONS;

EID: 85020423456     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.05.025     Document Type: Article

References (38)

1. AASLD/IDSA HCV Guidance Panel, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
2. Alavi, M., Raffa, J., Deans, G.D., Lai, C., Krajden, M., Dore, G.J., Grebely, J., Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver International 34:8 (2014), 1198–1206.
3. Arnsten, J.H., Demas, P.A., Farzadegan, H., Grant, R.W., Gourevitch, M.N., Chang, C.J., Schoenbaum, E.E., Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases 33:8 (2001), 1417–1423.
4. Blach, S., Zeuzem, S., Manns, M.P., Razavi, H.A., Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Polaris Observatory HCV Collaborators. Lancet Gastroenterology & Hepatology 2 (2017), 161–176.
5. Brown, M.T., Bussell, J.T., Medication adherence: WHO cares?. Mayo Clinic Proceedings 86 (2011), 304–314.
6. Charlebois, A., Lee, L., Cooper, E., Mason, K., Powis, J., Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. Journal of Viral Hepatitis 19:12 (2012), 836–842.
7. Dilorenzo, T., Halper, J., Picone, M.A., Reliability and validity of the multiple sclerosis quality of life inventory in older individuals. Disability and Rehabilitation 25:16 (2003), 891–897.
8. Dodd, Z., Banga, C.A., Mason, K., Meaney, C., Leszcz, L., Sockalingam, S., Engagement in group psychotherapy among marginalized individuals with hepatitis C. International Journal of Group Psychotherapy 66:3 (2016), 338–360.
9. Dore, G., C Edge Co-Star: Adherence and drug use in HCV-infected persons on opioid agonist therapy receiving elbasvir/grazoprevir fixed dose combination for 12 weeks. Paper presented at the 4th International Symposium on Hepatitis Care in Substance Users, Sydney, Australia, 2015 Presentation retrieved from: https://www.eiseverywhere.com/file_uploads/3f3623614b2115f0d3cf584977e25537_GregDore.pdf.
10. Dore, G., C-EDGE CO-STAR: Efficacy of grazoprevir/elbasvir fixed dose combination for 12 weeks in HCV-infected persons who inject drugs on opioid agonist therapy. Paper presented at 66th Annual Meeting of the American Association for the Study of Liver Disease, San Francisco, U.S.A., 2015 Presentation retrieved from: http://www.natap.org/2015/AASLD/AASLD_08.htm.
11. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., on behalf of the C.E.C.O.S.S.G, Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial. Annals of Internal Medicine 165:9 (2016), 625–634.
12. European Association for the Study of the Liver (EASL), EASL recommendations on treatment of hepatitis C 2016. Journal of Hepatology 66 (2017), 153–194.
13. Grebely, J., Raffa, J.D., Lai, C., Krajden, M., Kerr, T., Fischer, B., Tyndall, M.W., Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. Journal of Viral Hepatitis 16:5 (2009), 352–358.
14. Grebely, J., On-treatment illicit drug use did not impact treatment outcome during therapy with ledipasvir/sofosbuvir with or without ribavirin in the phase 3 ION-1 study. Paper presented at The International Liver Congress, European Association for the Study of the Liver, Barcelona, Spain, 2016 Presentation retrieved from: http://www.natap.org/2016/EASL/EASL_115.htm.
15. Grebely, J., Mauss, S., Brown, A., Bronowicki, J.P., Puoti, M., Wyles, D., Dore, G.J., Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials. Clinical Infectious Diseases 63:11 (2016), 1405–1411.
16. Hendershot, C.S., Stoner, S.A., Pantalone, D.W., Simoni, J.M., Alcohol use and antiretroviral adherence: Review and meta-analysis. Journal of Acquired Immune Deficiency Syndrome 52:2 (2009), 180–202.
17. International Network on Hepatitis in Substance Users (INHSU), Recommendations for the management of hepatitis C virus infection among people who inject drug. Clinical Infectious Disease 57 (2013), 129–137.
18. Iversen, J., Grebely, J., Topp, L., Wand, H., Dore, G., Maher, L., Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011. Journal of Viral Hepatitis 21:3 (2014), 198–207.
19. Khandor, E., Mason, K., Chambers, C., Rossiter, K., Cowan, L., Hwang, S.W., Access to primary health care among homeless adults in Toronto, Canada: Results from the Street Health survey. Open Medicine 5:2 (2011), e94–e103.
20. Litwin, A.H., High rates of sustained virological response in people who inject drugs treated with all-oral direct acting antiviral regimens. Paper presented at the 5th International Symposium on Hepatitis Care in Substance Users, Oslo, Norway, 2016 Presentation retrieved from: https://www.eiseverywhere.com/file_uploads/ec626d74ab97207d900ddc93eeb18144_166_AlainLitwin.pdf.
21. Marcellin, P., Chousterman, M., Fontanges, T., Ouzan, D., Rotily, M., Varastet, M., CheObs Study Group, Adherence to treatment and quality of life during hepatitis C therapy: A prospective, real-life, observational study. Liver International 31:4 (2011), 516–524.
22. Marrie, R.A., Miller, D.M., Chelune, G.J., Cohen, J.A., Validity and reliability of the MSQ LI in cognitively impaired patients with multiple sclerosis. Multiple Sclerosis Journal 9:6 (2003), 621–626.
23. Mason, K., Dodd, Z., Altenberg, J., Meaney, C., Millson, P., Powis, J., Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support. International Journal of Drug Policy 26:10 (2015), 1007–1013.
24. McGowan, C., Fried, M., Barriers to hepatitis C treatment. Liver International 32:1 (2012), 151–156.
25. Morris, L., Smirnov, A., Kvassay, A., Leslie, E., Kavanagh, R., Najman, J., The impact of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors’ Health Network. International Journal of Drug Policy 47 (2017), 216–220.
26. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., Degenhardt, L., Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378:9791 (2011), 571–583.
27. Newman, A., Beckstead, S., Beking, D., Finch, S., Knorr, T., Lynch, C., Shore, R., Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre. Canadian Journal of Gastroenterology 27:4 (2013), 217–223.
28. Osterberg, L., Blaschke, T., Adherence to medication. New England Journal of Medicine 353 (2005), 487–497.
29. Petersen, T., Townsend, K., Gordon, L., Sidharthan, S., Silk, R., Nelson, A., Gross, C., Kohli, A., High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatology International 10:2 (2016), 310–319.
30. Read, P., Lothian, R., Chronister, K.J., Gilliver, R., Kearley, J., Dore, G.J., Delivery direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injection populations in a targeted primary health care setting. International Journal of Drug Policy 47 (2017), 209–215.
31. Ritvo, P.G., Fischer, J.S., Miller, D.M., Andrews, H., Paty, D.W., LaRocca, N.G., Multiple sclerosis quality of life inventory: A user's manual. 1997, National Multiple Sclerosis Society, New York.
32. Sarpel, D., Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. Paper presented at the American Association for the Study of Liver Disease Meeting 2016, Boston, USA, 2016 Presentation retrieved from: http://www.natap.org/2016/AASLD/AASLD_75.htm.
33. Sherbourne, C.D., Stewart, A.L., The MOS social support survey. Social Science & Medicine 32:6 (1991), 705–714.
34. Shi, L., Liu, J., Koleva, Y., Fonseca, V., Kalsekar, A., Pawaska, M., Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 28:12 (2010), 1097–1107.
35. Statistics Canada, Canadian Community Health Survey, Cycle 1.2. Mental health and well-being. 2003 Retrieved from Statistics Canada website: http://www23.statcan.gc.ca/imdb-bmdi/instrument/5015_Q1_V1.eng.pdf. (Accessed 30 November 2016).
36. Sullivan, M.J., Edgley, K., Dehoux, E., A survey of multiple sclerosis. Part I: Perceived cognitive problems and compensatory strategies use. Canadian Journal of Rehabilitation 4 (1990), 99–105.
37. Tran, B.X., Nguyen, L.T., Do, C.D., Nguyen, Q.L., Maher, R.M., Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS. BMC Public Health, 14(27), 2014.
38. Williams, A.B., Amico, K.R., Womack, J.A., A proposal for quality standards for measuring medication adherence in research. AIDS and Behavior 1 (2013), 284–297.